Literature DB >> 29616331

A proposed treatment algorithm for mild to moderate ulcerative colitis-with an emphasis on budesonide foam and mucosal healing.

Juris Pokrotnieks1,2, Stanislav Sitkin3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29616331     DOI： 10.1007/s00535-018-1458-y

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  7 in total

1.  Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.

Authors:  V Gross; S Bar-Meir; A Lavy; O Mickisch; Z Tulassay; L Pronai; L Kupcinskas; G Kiudelis; J Pokrotnieks; A Kovács; M Faszczyk; A Razbadauskas; B Margus; M Stolte; R Müller; R Greinwald
Journal:  Aliment Pharmacol Ther       Date:  2006-01-15       Impact factor: 8.171

2.  Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.

Authors:  William J Sandborn; Brian Bosworth; Salam Zakko; Glenn L Gordon; David R Clemmons; Pamela L Golden; Robert L Rolleri; Jing Yu; Andrew C Barrett; Enoch Bortey; Craig Paterson; William P Forbes
Journal:  Gastroenterology       Date:  2015-01-30       Impact factor: 22.682

3.  Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis.

Authors:  Simon Bar-Meir; Herma H Fidder; Mark Faszczyk; Gabriele Bianchi Porro; Giacomo C Sturniolo; Oliver Mickisch; Ralph Müller; Roland Greinwald; Yehuda Chowers; Volker Grobeta
Journal:  Dis Colon Rectum       Date:  2003-07       Impact factor: 4.585

Review 4.  Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis.

Authors:  Shailja C Shah; Jean-Frederic Colombel; Bruce E Sands; Neeraj Narula
Journal:  Clin Gastroenterol Hepatol       Date:  2016-01-30       Impact factor: 11.382

5.  Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.

Authors:  Brian P Bosworth; William J Sandborn; David T Rubin; Joseph R Harper
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

6.  Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.

Authors:  Makoto Naganuma; Nobuo Aoyama; Tomohiro Tada; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2017-08-04       Impact factor: 7.527

7.  Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.

Authors:  Makoto Naganuma; Nobuo Aoyama; Yasuo Suzuki; Haruo Nishino; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2015-11-16       Impact factor: 9.071
  7 in total
  1 in total

1.  Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy.

Authors:  Tomoyoshi Shibuya; Kei Nomura; Koki Okahara; Keiichi Haga; Osamu Nomura; Takashi Murakami; Shino Uchida; Tomohiro Kodani; Dai Ishikawa; Naoto Sakamoto; Tatsuo Ogihara; Taro Osada; Akihito Nagahara
Journal:  Med Sci Monit       Date:  2019-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.